ArticleScientific reports2025
Piceatannol and its analogues alleviate Staphylococcus aureus pathogenesis by targeting β-lactamase biofilms and α-hemolysin.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The toxic effects of α-hemolysin and β-hemolysin produced byFrontiers in immunology · 2026Review
- Antifungal Effects of Pterostilbene onJournal of fungi (Basel, Switzerland) · 2025Article
- DisarmingPathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
β-Lactamases, biofilms and toxins pose challenges for combating S. aureus infection. Thus, identifying inhibitors that can restore bacterial sensitivity to antibiotics, destroy biofilms, and antitoxins is a promising way to develop alternative agents. In this study, we found that piceatannol (pit), along with its analogues resveratrol (ret) and pterostilbene (pts) bind with β-lactamase to inhibit its activity, and 96TYR, 58ILE and 66LYS were identified as the critical binding residues. Pit and pts reduced the ampicillin (Amp) and gentamicin (Gm) MICs against S. aureus and enhanced the bactericidal ability of Amp. Pit and its analogues inhibited the formation of S. aureus USA300. In addition, the pit analogues bound with α-hemolysin and suppressed the hemolysis activity of the bacterial culture supernatant. The mechanism analysis revealed that pit exhibited multiple potential binding modes with α-hemolysin. Pit significantly decreased the cytotoxicity and the adherence effect mediated by S. aureus and increased the survival rate of Galleria mellonella that infected with S. aureus, the pathological tissue damage of Galleria mellonella was alleviated by treatment with pit alone or in combination with Amp. Taken together, our findings identify promising compounds for the development of S. aureus infection inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.